Company Description

Dracen Pharmaceuticals is a private clinical-stage biotech company developing DRP-104, a special “prodrug” version of DON. DRP-104 is an inactive compound that is converted into DON by metabolic processes. DRP-104 is activated within tumors and mostly remains inactivated in other tissues; as a result, DRP-104 delivers DON into tumors while sparing healthy tissues.